New hope for Tough-to-Treat colon cancer: experimental drug combo enters final testing
NCT ID NCT07549412
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has progressed after prior therapies. About 1,020 participants will be randomly assigned to one of three treatment groups. The main goal is to see if the new drug helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
precemtabart tocentecan (a drug), bevacizumab, and trifluridine/tipiracil
What this could lead to
If successful, this could offer a new treatment option for people with metastatic colorectal cancer who have already tried standard therapies, potentially extending survival.
What could go wrong
This is a large Phase 3 trial, but the experimental drug is still unproven. It may not improve survival or could cause side effects. Results may take years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GenesisCare North Shore (Oncology)
RECRUITINGSt Leonards, New South Wales, 2065, Australia
-
Icon Cancer Centre Chermside
RECRUITINGChermside, Queensland, 4032, Australia
-
Illinois CancerCare PC
RECRUITINGPeoria, Illinois, 61615-7822, United States
-
Missouri Cancer Associates - 150518964
RECRUITINGColumbia, Missouri, 65201, United States
-
Profound Research LLC at Cancer and Leukemia Center
RECRUITINGSterling Heights, Michigan, 48098, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Texas Oncology DFW
RECRUITINGBedford, Texas, 75246, United States
-
Texas Oncology- San Antonio
RECRUITINGSan Antonio, Texas, 78240, United States